A Study of Ramelteon in Chinese Patients With Chronic Insomnia

Inclusion Criteria:

• Male or female aged ≥ 18 years old.

• Chronic insomnia disorder diagnosed according to International Classification ofSleep Disorders, Third Edition, Text Revision (ICSD-3-TR) criteria.

• Self-reported history of all the following on at least 3 nights per week within 4weeks prior to screening: subjective sleep latency (sSL) greater than or equal to 30minutes, and subjective total sleep time (sTST) less than or equal to 6.5 hours pernight.

• Meeting all the following sleep parameters on the 2 PSG nights during the run-inperiod: mean latency to persistent sleep (LPS) ≥ 20 min (with neither of the twonights < 15 min), and mean wake after sleep onset (WASO) ≥ 30 min (with neither ofthe two nights < 20 min).

• Usual bedtime between 20:30 and 01:00, and regular time in bed between 6.5 and 9 h.

• Insomnia Severity Index score≥15 at screening and on Day 1 of the treatment period.

• Understand the study procedures and methods, voluntarily participate in this trial,and sign the informed consent.

Exclusion Criteria:

• Use of ramelteon within 30 days prior to screening.

• Previous non-responders to melatonin receptor agonist therapy.

• Known hypersensitivity to ramelteon or related compounds, including melatonin.

• Sleep schedule changes required by employment (e.g. shift worker), or has flownacross greater than three time zones (mainland China is considered as 1 time zone)within 30 days prior to screening and during the study period; or specialprofessionals who need to operate machinery during the study period, such asprofessional drivers, high-altitude operators, etc.

• Participated in a weight loss program or has substantially altered their exerciseroutine within 30 days prior to screening and during the study period.

• Previous history of nervous system disorders such as epilepsy, schizophrenia,bipolar mental disorder, neurodevelopmental retardation, and cognitive disorder, orprevious history of other mental illness that may affect the safety of the subjectsor interfere with the study assessments in the opinion of the investigator.

• Previous history of other sleep disorders secondary to other diseases includingmoderate to severe obstructive sleep apne, circadian rhythm sleep disturbances,paroxysmal sleeping sickness, and restless legs syndrome.

• Apnea-hypopnea index (AHI) and periodic limb movement index (PLMI) > 15 times/hourdetected by PSG monitoring during the run-in period.

• Have previous complex sleep behaviors, such as sleep driving, sleep eating, andsleep phone calls.

• Hamilton Anxiety Scale (HAMA) score ≥ 14 and Hamilton Depression Scale (HAMD) score ≥ 18 at screening.

• Have serious diseases of cardiovascular system, digestive system, respiratorysystem, urinary system, endocrine system, immune system, etc., which are notsuitable for the study judged by the investigators.

• AST or ALT > 3 × ULN, and TBIL > 2 × ULN.

• Patients with HIV or syphilis infection.

• Use of any hypnotics, antidepressants, antipsychotic drugs, anticholinergics,memory-enhancing drugs, antihistamines, centrally acting analgesics, centrallyacting muscle relaxants, central nervous system stimulants, strong CYP1A2inhibitors, strong CYP2C9 inhibitors, strong CYP3A4 inhibitors, strong CYP inducers,or any other therapies for insomnia disorder within 1 week prior to the run-inperiod or within 5 half-lives of the investigational product, whichever is longer.

• Requirement of taking any prohibited medication during study period.

• History of drug abuse within 1 year prior to screening, or positive urine drugscreening.

• History of alcohol abuse within 1 year prior to screening, or unwilling to followalcohol restriction during the study period.

• Regular daily consumption of excessive tea and coffee drinks, or unwilling to followtea/coffee restriction during the study period.

• History of smoking addiction or unwilling to follow tobacco restriction during thestudy period.

• Participated in any other investigational study and taken any investigational drugwithin 1 month or 5 half-lives prior to screening, whichever is longer.

• Pregnant or lactating women, or planning to have children or both men ofreproductive potential and women of childbearing potential disagree to use ≥1effective contraception throughout the study and within 3 months after the end ofthe study.

• MEQ-19 score ≤ 49.

• Other conditions that are not considered appropriate by the investigator.